BOSTON, May 15 /PRNewswire/ -- Surface Logix today announced that Jim
Mahoney, President & CEO, will be stepping down from his current position
to pursue other interests. Mr. Mahoney will maintain a consulting
relationship with the company for the foreseeable future. Steven Gillis,
Ph.D., Managing Director at ARCH Venture Partners will assume the role of
Executive Chairman until a new CEO is appointed.
"The Board, shareholders and employees of Surface Logix would like to
thank Jim for his considerable contributions to the Company. He led the
transformation of Surface Logix from a chemistry platform to a small
molecule drug discovery and development company with two internally
generated programs having completed several successful Phase 2a clinical
trials. Everyone at Surface Logix wishes Jim well in his decision to pursue
other interests," said Steven Gillis. "Surface Logix is well positioned to
move forward both of our cardiovascular programs, SLx-4090 and SLx-2101,
into Phase 2b studies. Both programs have demonstrated clear efficacy and
excellent tolerability and safety in clinical trials to date. We will also
continue our research activities aimed at bringing exciting new programs to
the clinic."
About Surface Logix, Inc.
Surface Logix, Inc. uses its expertise in biophysical chemistry to
create and develop novel small molecule drugs (NCEs) with superior
drug-like properties that are clearly differentiated from competitive
products. The company is advancing multiple internal programs focused
primarily on cardiovascular, metabolic, oncologic and fibrotic diseases.
For more information, please visit http://www.surfacelogix.com .
Contact:
Leland Webster, Ph.D., M.B.A.
Surface Logix, Inc.
Vice President, Corporate Development
617.746.8520
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
781-235-3060
SOURCE Surface Logix, Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
Leland Webster, Ph.D., M.B.A., Vice
President, Corporate Development of Surface Logix, Inc.,
+1-617-746-8520; or Media: Kari Watson of MacDougall Biomedical
Communications Inc., +1-781-235-3060, kwatson@macbiocom.com
|
